Veriphi Shareholder Update: 7 October 2017

Analyser Performance Improves. With the conclusion of the first round of tests at Auckland City Hospital, the team have taken a closer look at the data variance (spread) for each drug. Analysis, by our lead scientist Dr Ray Simpkin of Callaghan Innovation, identified a source of thermal drift in the data. This was addressed by componentry changes, implemented newly minted …

Veriphi Shareholder Update: 24 September 2017

Hospital Test Results. We have completed our first preliminary tests at Auckland City Hospital. In blind trials we tested saline and four oncology drugs at full concentration. All 5 drugs and solutions were successfully identified in blind trials. This is a great first step.We also tested doxorubicin an enantiomer (mirror image) of one of the 4 drugs epirubicin. They could …

Veriphi Shareholder Update: 7 August 2017

Share Sale. Expressions of interest in in purchasing shares belonging to Kees Klein (Novel Services) has been high. The offer, which expired at 5pm on Friday 4 August, was oversubscribed. Forty-four shareholders expressed interest in acquiring more than 400,000 shares at the discounted price. The 371,864 shares available will be allocated on a prorata basis, for those who have expressed …

Veriphi Shareholder Update: 24 July 2017

ACH Hospital Pharmacy Trials.  Trials at Auckland City Hospital commenced on Saturday 22 July, on 5 oncology drugs. As a first step, we captured preliminary indicative data on each of the drugs, each in a single container, to see how well separated the drug signatures are. The initial data showed good separation between all drugs with less separation between two …